Associate Professor, Medicine, UCLA School of Medicine
Gastroenterology
Dr. Eric A. Vasiliauskas, MD
|
|
Give Review
Dr. Eric A. Vasiliauskas works in the field of Gastroenterology. He went to University of Illinois College of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Eric Vasiliauskas is a published doctor. He has 42 papers published. The most current publication "Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulc..." Eric Vasiliauskas accepts Medicare.
Publications
- Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulc...
- Editorial: is thalidomide a good option for patients with refractory Crohn's Disease? Authors' reply.
- Long-term outcomes of thalidomide in refractory Crohn's Disease.
- Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel Disease patients.
- Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel Disease.
- Assessing health status in inflammatory bowel Disease using a novel single-item numeric rating scale.
- Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn's Disease.
- Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's Disease?
- Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's Disease.
- Genetic predictors of medically refractory Ulcerative colitis.
- Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's Disease.
- A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis.
- New clinical method for distinguishing D-IBS from other gastroIntestinal conditions causing diarrhea: the LA/IBS diagnostic strategy.
- Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel Disease.
- Capsule endoscopy in patients with Crohn's Disease: diagnostic yield and safety.
- A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel Disease-unclassified and indeterminate colitis.
- Linkage of Crohn's Disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.
- Family history and serology predict Crohn's Disease after ileal pouch-anal anastomosis for ulcerative colitis.
- Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with Ulcerative colitis?
- Anti-flagellin (CBir1) phenotypic and genetic Crohn's Disease associations.
- Predicting a change in diagnosis from ulcerative colitis to Crohn's Disease: a nested, case-control study.
- NOD2 variants and antibody response to microbial antigens in Crohn's Disease patients and their unaffected relatives.
- Antibodies to I2 predict clinical response to fecal diversion in Crohn's Disease.
- Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
- Patients with inflammatory bowel Disease are at risk for vaccine-preventable illnesses.
- Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's Disease.
- Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's Disease.
- Elevated platelet count before ileal pouch-anal anastomosis for Ulcerative colitis is associated with the development of chronic pouchitis.
- Safety and efficacy of adalimumab (D2E7) in Crohn's Disease patients with an attenuated response to infliximab.
- Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel Disease.
- A pilot study of adalimumab in infliximab-allergic patients.
- The spectrum of gastrointestinal toxicity and effect on Disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel Disease.
- High incidence of anergy in inflammatory bowel Disease patients limits the usefulness of PPD screening before infliximab therapy.
- Association of antibody responses to microbial antigens and complications of small bowel Crohn's Disease.
- Early nodular hyperplasia of the liver occurring with inflammatory bowel Diseases in association with thioguanine therapy.
- Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel Disease.
- 6-thioguanine can cause serious liver injury in inflammatory bowel Disease patients.
- Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
- Mutations in NOD2 are associated with fibrostenosing Disease in patients with Crohn's Disease.
- 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel Disease.
- Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis.
Schools
University of Illinois At Chicago College of Medicine
Procedures Preformed
- Anoscopy
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
Conditions Treated
- Anemia
- Benign Neoplasm of the Digestive System
- Cirrhosis
- Crohn's Disease (Regional Enteritis)
- View All
Doctors Specialties
- Pediatric Gastroenterology
- Gastroenterology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Children's Hospital of Los Angeles -
University of Illinois College of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1114955135 | |
| NPPES Provider LastName | VASILIAUSKAS | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 900481804 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 420.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 9.52 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114955135 |
| Last Name Of The Provider | VASILIAUSKAS |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. Marla Dubinsky, MD |
|
|
Dr. Walid Ayoub, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laith H. Jamil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Collins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vinay Sundaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen J. Pandol, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Leslie J. Schoenfield, MD |
|
|
Dr. Mamatha R. Sadda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle P. Vu, MD |
|
|
Dr. Tressia C. Hing, MD |
|
|
Dr. Atul Khanna, MD |
|
|
Federico Villamil |